Understanding dyspnea in patients with idiopathic pulmonary fibrosis
Dyspnea in Idiopathic Pulmonary Fibrosis (IPF): Multidimensional Assessment and Correlations With Lung Function
University Hospital, Lille · NCT04864990
This study looks at how shortness of breath changes over six months in people with idiopathic pulmonary fibrosis to better understand their experience and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Lille (other) |
| Locations | 1 site (Lille) |
| Trial ID | NCT04864990 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the evolution of dyspnea in patients diagnosed with idiopathic pulmonary fibrosis (IPF) over a six-month period. It will assess both the sensory and affective dimensions of dyspnea, examining how these components change and their relationship with respiratory function and ventilation mechanics. By utilizing innovative techniques such as impulse oscillometry, the study seeks to provide a deeper understanding of dyspnea beyond traditional measures. The findings could help tailor more effective management strategies for patients suffering from this debilitating symptom.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with idiopathic pulmonary fibrosis who experience dyspnea at rest or on exertion.
Not a fit: Patients with other significant chronic conditions causing dyspnea, such as COPD or heart failure, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of dyspnea in IPF patients, enhancing their quality of life.
How similar studies have performed: While there have been studies on dyspnea in lung diseases, this specific approach focusing on the multidimensional aspects of dyspnea in IPF is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of IPF according to ATS/ERS guidelines * dyspnea at rest (VAS ≥ 1) or on exertion (mMRC ≥ 1) Exclusion Criteria: * diffuse interstitial lung disease other than IPF * other significant chronic pathology that may cause dyspnea: chronic obstructive pulmonary disease, asthma, heart failure, anemia, obesity (non-exhaustive list), except for pulmonary hypertension
Where this trial is running
Lille
- Hop Calmette Chu Lille — Lille, France (RECRUITING)
Study contacts
- Principal investigator: Cécile Chenivesse, MD,PhD — University Hospital, Lille
- Study coordinator: Cécile Chenivesse, MD,PhD
- Email: cecile.chenivesse@chru-lille.fr
- Phone: 0320445962
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pulmonary Fibrosis